Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study

Simple item page
dc.contributor.authorErkurt, MA
dc.contributor.authorBerber, I
dc.contributor.authorTekgunduz, E
dc.contributor.authorDogu, MH
dc.contributor.authorKorkmaz, S
dc.contributor.authorDemir, C
dc.contributor.authorYilmaz, M
dc.contributor.authorAkay, OM
dc.contributor.authorPala, C
dc.contributor.authorBilen, Y
dc.contributor.authorKaya, E
dc.contributor.authorSari, I
dc.contributor.authorSencan, M
dc.contributor.authorKuku, I
dc.contributor.authorAltuntas, F
dc.contributor.authorDal, MS
dc.contributor.authorAydogdu, I
dc.date.accessioned2025-04-10T10:37:13Z
dc.date.available2025-04-10T10:37:13Z
dc.description.abstractWe investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. (c) 2016 Elsevier Ltd. All rights reserved.
dc.identifier.issn1473-0502
dc.identifier.urihttp://hdl.handle.net/20.500.14701/42886
dc.language.isoEnglish
dc.titlePrimary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu